A new international study reveals a possible connection between GLP1 receptor agonists--used in drugs like Ozempic--and increased risk of depression and suicidal ideation, especially in people with low dopamine function. Researchers used advanced pharmacogenomic tools to identify genetic pathways that may be vulnerable to dopamine dysregulation when exposed to these medications.
A new international study reveals a possible connection between GLP1 receptor agonists--used in drugs like Ozempic--and increased risk of depression and suicidal ideation, especially in people with low dopamine function. Researchers used advanced pharmacogenomic tools to identify genetic pathways that may be vulnerable to dopamine dysregulation when exposed to these medications.
Share this Article
Recommended